{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:40:00Z","timestamp":1794620400713,"version":"4.9.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30AG072975"],"award-info":[{"award-number":["P30AG072975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30AG010161"],"award-info":[{"award-number":["P30AG010161"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AG055909"],"award-info":[{"award-number":["R01AG055909"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AG080667"],"award-info":[{"award-number":["R01AG080667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"DOI":"10.1186\/s13024-025-00910-4","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:02:52Z","timestamp":1763078572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Plasma TDP-43 is a potential biomarker for advanced limbic-predominant age-related TDP-43 encephalopathy neuropathologic change"],"prefix":"10.1186","volume":"20","author":[{"given":"Jijing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Young-Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Sik","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"910_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327.","journal-title":"Brain"},{"key":"910_CR2","doi-asserted-by":"publisher","first-page":"e14202","DOI":"10.1002\/alz.14202","volume":"21","author":"DA Wolk","year":"2025","unstructured":"Wolk DA, Nelson PT, Apostolova L, Arfanakis K, Boyle PA, Carlsson CM, Corriveau-Lecavalier N, Dacks P, Dickerson BC, Domoto-Reilly K, et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025;21:e14202.","journal-title":"Alzheimers Dement"},{"key":"910_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-024-00419-8","volume":"13","author":"JI Lopez-Carbonero","year":"2024","unstructured":"Lopez-Carbonero JI, Garcia-Toledo I, Fernandez-Hernandez L, Bascunana P, Gil-Moreno MJ, Matias-Guiu JA, Corrochano S. In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use. Transl Neurodegener. 2024;13:29.","journal-title":"Transl Neurodegener"},{"key":"910_CR4","doi-asserted-by":"publisher","first-page":"e12365","DOI":"10.1002\/dad2.12365","volume":"14","author":"CN Winston","year":"2022","unstructured":"Winston CN, Sukreet S, Lynch H, Lee VM, Wilcock DM, Nelson PT, Rissman RA. Evaluation of blood-based, extracellular vesicles as biomarkers for aging-related TDP-43 pathology. Alzheimers Dement (Amst). 2022;14:e12365.","journal-title":"Alzheimers Dement (Amst)"},{"key":"910_CR5","doi-asserted-by":"crossref","unstructured":"Thomas EV, Han C, Kim WJ, Asress S, Li Y, Taylor JA, Gearing M, Fournier CN, McEachin ZT, Seyfried NT, Glass JD. ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression. Ann Clin Transl Neurol. 2025.","DOI":"10.1002\/acn3.70001"},{"key":"910_CR6","doi-asserted-by":"publisher","first-page":"e70166","DOI":"10.1002\/alz.70166","volume":"21","author":"RE Rea Reyes","year":"2025","unstructured":"Rea Reyes RE, Wilson RE, Langhough RE, Studer RL, Jonaitis EM, Oomens JE, Planalp EM, Bendlin BB, Chin NA, Asthana S, et al. Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for alzheimer\u2019s disease and related dementias. Alzheimers Dement. 2025;21:e70166.","journal-title":"Alzheimers Dement"},{"key":"910_CR7","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.3233\/JAD-179939","volume":"64","author":"DA Bennett","year":"2018","unstructured":"Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious orders study and rush memory and aging project. J Alzheimers Dis. 2018;64:S161\u201389.","journal-title":"J Alzheimers Dis"},{"key":"910_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.neuron.2025.03.034","volume":"113","author":"AM Lish","year":"2025","unstructured":"Lish AM, Grogan EFL, Benoit CR, Pearse RV 2nd, Heuer SE, Luquez T, Orme GA, Galle PC, Milinkeviciute G, Green KN, et al. CLU alleviates alzheimer\u2019s disease-relevant processes by modulating astrocyte reactivity and microglia-dependent synaptic density. Neuron. 2025;113:1925\u201346. e1911.","journal-title":"Neuron"},{"key":"910_CR9","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/jamaneurol.2013.3961","volume":"70","author":"RS Wilson","year":"2013","unstructured":"Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, Schneider JA. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70:1418\u201324.","journal-title":"JAMA Neurol"},{"key":"910_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601.","journal-title":"Brain"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00910-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00910-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00910-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:02:53Z","timestamp":1763078573000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00910-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00910-4","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study protocols and procedures were approved by the Institutional Review Board at Rush University Medical Center, and all participants signed written informed consent and the Anatomical Gift Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"Dr. Schneider serves as a consultant to Lantheus. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}